Neupro (UCB/Otsuka) is a transdermal formulation of the non-ergoline dopamine receptor agonist rotigotine. Applied once daily, the patch allows continuous drug administration over 24 hours and avoids the fluctuation in dopaminergic stimulation resulting from numerous oral doses. Neupro is approved for monotherapy for early-stage Parkinson’s disease patients and as an adjunctive therapy for advanced patients receiving concomitant levodopa.
Neupro was obtained by UCB through its acquisition of Schwarz Pharma in 2006, gaining first approval in the EU in February 2006 and in the US in May 2007 for the treatment of early-stage idiopathic Parkinson’s disease. Later, in April 2012, the US Food and Drug Administration approved Neupro for the treatment of the signs and symptoms of advanced-stage Parkinson’s disease and as a treatment for moderate to severe primary restless legs syndrome (RLS). Otsuka holds exclusive rights to develop and market Neupro in Japan, and the company received approval for Neupro in this market in December 2012 in both Parkinson’s disease and RLS.
LIST OF FIGURES
9 Figure 1: Neupro for Parkinson’s disease – SWOT analysis
10 Figure 2: Datamonitor Healthcare’s drug assessment summary of Neupro for Parkinson’s disease
11 Figure 3: Datamonitor Healthcare’s drug assessment summary of Neupro for Parkinson’s disease
13 Figure 4: Neupro sales for Parkinson’s disease across the US, Japan, and five major EU markets, by country, 2016–25
LIST OF TABLES
6 Table 1: Neupro drug profile
7 Table 2: Neupro pivotal trial data in Parkinson’s disease
14 Table 3: Neupro sales for Parkinson’s disease across the US, Japan, and five major EU markets, by country ($m), 2016–25
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.